ReviewSurvey of ophthalmology
Molecular mechanisms and treatments for ocular symblephara.
Review in Survey of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Corneal regenerative contribution of endogenous and grafted limbal-corneal cells in a mouse model of simple limbal-corneal epithelial transplantation.Stem cells translational medicine · 2026Article
- Alteration of Gene Expression in Pathological Keratinization of the Ocular Surface.Investigative ophthalmology & visual science · 2024Article
- Alkali burn injury model of meibomian gland dysfunction in mice.International journal of ophthalmology · 2024Article
- Management of Symblepharon Prior to Keratoprosthesis in Chronic Ocular Burns: A Sequential Approach.Cureus · 2022Article
- PNP Hydrogel Prevents Formation of Symblephara in Mice After Ocular Alkali Injury.Translational vision science & technology · 2022Article
- Symblepharon as Ocular Manifestation Post Stevens-Johnson Syndrome: A Rare Case.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
There are currently no effective methods to prevent or durably treat ocular symblephara, the adhesions between the palpebral and bulbar conjunctiva. How symblephara form at the molecular level is largely unknown. We present here an overview of current clinical symblephara treatments and describe potential molecular mechanisms behind conjunctival adhesion formation that may inform future symblephara treatment and prevention options. Understanding how symblephara form at the molecular level will facilitate treatment development. Preventative therapies may be possible by targeting symblephara progenitor cells immediately after injuries, while novel therapeutics should be aimed at modulating TGF-β pathways and effector cells in conjunctival scarring to treat symblephara formation more effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.